Stada and Xbrane Add Two To Biosimilar Development Alliance

 
• By Aidan Fry

Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.

Sum
Stada and Xbrane have added certolizumab and nivolumab to their existing biosimilar alliance covering ranibizumab • Source: Shutterstock

More from Deals

More from Business